Effectiveness and Safety of Glecaprevir/Pibrentasvir in Italian Children and Adolescents With Chronic Hepatitis C: A Real‐Word, Multicenter Study
Liver International · 2025
DOI: 10.1111/liv.16180 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Liver International, 2025. Verfasst von Mariangela Stinco und 26 weiteren Autor:innen. Beteiligte Einrichtung: Liver Unit, Meyer Children's Hospital IRCCS, Florence, Italy. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Pyrrolidines, Antiviral Agents, Quinoxalines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background & Aims Glecaprevir/Pibrentasvir (GLE/PIB) has been approved by the European Medicine Agency (EMA) and by the US Food and Drug Administration (US‐FDA) for the treatment of children and adolescents from 3 years of age with chronic hepatitis C virus (CHC) infection. The aim of this study was to confirm the real‐world effectiveness and safety of GLE/PIB in children and adolescents (3 to < 18 years old) with CHC.
Methods
This prospective, multicentre study involved 11 Italian centres. Children and adolescents (from 3 to < 18 years of age) received a weight‐based dose (up to 300/120 mg) of GLE/PIB once daily for 8 weeks. The effectiveness endpoint was sustained virological response 12 weeks after the end of treatment (SVR12). Safety was assessed by adverse events (AE) and clinical/laboratory data.
Results
Sixty‐one patients (median age 12 years, interquartile range 5) were enrolled and treated between June 2020 and October 2023. Genotype distribution was as follows: 24/61 genotype 1 (39.4%), 13/61 genotype 2 (21.3%), 18/61 genotype 3 (29.5%) and 6/61 genotype 4 (9.8%). Sixty (98.4%) patients completed treatment and follow‐up. SVR12 was obtained by 60/61 patients (98.4%). One patient died because of an oncological illness while on treatment. AE occurred in 13.1% of the patients, were mild and no patients prematurely stopped treatment.
Conclusions
This study confirmed the real‐life effectiveness and safety of the 8‐week therapy with GLE/PIB for treatment of CHC in children and adolescents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
- Pediatric Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Pediatric Infectious Diseases Unit, Regina Margherita Children's Hospital, University of Turin, Turin, Italy.
- Hepatology, Gastroenterology and Transplantation Unit, Hospital Papa Giovanni XXIII, Bergamo, Italy.
- Institute for Maternal and Child Health-IRCCS Burlo Garofolo, Trieste, Italy.
- Pediatric Department, University of Trieste, Trieste, Italy.
ORCID-Profile: Mariangela Stinco, Lorenzo D'Antiga, Francesca Musto, Federica Zallocco, Mara Cananzi, Giuseppe Indolfi
Zitieren
APA
Stinco, M., Rubino, C., Bartolini, E., Nuti, F., Paolella, G., Nebbia, G., Silvestro, E., Garazzino, S., Nicastro, E., D'Antiga, L., Zanchi, C., Morra, L., Iorio, R., Di Dato, F., Maggiore, G., Sartorelli, M. R., Comparcola, D., Stracuzzi, M., Giacomet, V., …, & Indolfi, G. (2025). Effectiveness and Safety of Glecaprevir/Pibrentasvir in Italian Children and Adolescents With Chronic Hepatitis C: A Real‐Word, Multicenter Study. Liver International. https://doi.org/10.1111/liv.16180
Vancouver
Stinco M, Rubino C, Bartolini E, Nuti F, Paolella G, Nebbia G, et al. Effectiveness and Safety of Glecaprevir/Pibrentasvir in Italian Children and Adolescents With Chronic Hepatitis C: A Real‐Word, Multicenter Study. Liver International. 2025. doi:10.1111/liv.16180
BibTeX
@article{Stinco2025,
author = {Stinco, Mariangela and Rubino, Chiara and Bartolini, Elisa and Nuti, Federica and Paolella, Giulia and Nebbia, Gabriella and Silvestro, Erika and Garazzino, Silvia and Nicastro, Emanuele and D'Antiga, Lorenzo and Zanchi, Chiara and Morra, Laura and Iorio, Raffaele and Di Dato, Fabiola and Maggiore, Giuseppe and Sartorelli, Maria Rita and Comparcola, Donatella and Stracuzzi, Marta and Giacomet, Vania and Musto, Francesca and Pinon, Michele and Calvo, Pierluigi and Carloni, Ines and Zallocco, Federica and Cananzi, Mara and Trapani, Sandra and Indolfi, Giuseppe},
title = {Effectiveness and Safety of Glecaprevir/Pibrentasvir in Italian Children and Adolescents With Chronic Hepatitis C: A Real‐Word, Multicenter Study},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.16180}
}
EUVIMED